Treace Medical Concepts closed on a $50 million non-dilutive term loan agreement. After retiring existing term debt, remaining proceeds will fuel the company’s sales, marketing, product development and clinical programs.
The financing will provide Treace with additional growth capital to support commercialization of its Lapiplasty® System, the first procedure that corrects all three dimensions of bunion deformity and creates durable results for patients through a reproducible procedure for physicians.
Treace also announced the expansion of available funds under its existing revolving line of credit to up to $10 million.
Treace Medical Concepts closed on a $50 million non-dilutive term loan agreement. After retiring existing term debt, remaining proceeds will fuel the company's sales, marketing, product development and clinical programs.
Treace Medical Concepts closed on a $50 million non-dilutive term loan agreement. After retiring existing term debt, remaining proceeds will fuel the company’s sales, marketing, product development and clinical programs.
The financing will provide Treace with additional growth capital to support commercialization of its Lapiplasty® System, the first procedure that corrects all three dimensions of bunion deformity and creates durable results for patients through a reproducible procedure for physicians.
Treace also announced the expansion of available funds under its existing revolving line of credit to up to $10 million.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
Copy to clipboard 
